Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis
Grover S, Dougan M, Tyan K, Giobbie‐Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin‐Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis. Cancer 2020, 126: 3758-3767. PMID: 32567084, PMCID: PMC7381363, DOI: 10.1002/cncr.32966.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalColitisCTLA-4 AntigenFemaleHumansImmune Checkpoint InhibitorsLymphocytesMaleMelanomaMiddle AgedNeutrophilsProgrammed Cell Death 1 ReceptorVitamin DConceptsImmune checkpoint inhibitorsVitamin D useVitamin D intakeICI colitisD intakeD useDiscovery cohortDevelopment of ICIsImmune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisCombination immune checkpoint inhibitorsMultivariable logistic regression analysisDana-Farber Cancer InstituteRisk of colitisMultivariable regression analysisLogistic regression analysisMassachusetts General HospitalRegression analysisCheckpoint inhibitorsLaboratory characteristicsPD-1Ulcerative colitisLymphocyte ratioMelanoma patientsVitamin D